Fulgent Genetics Raises FY24 Adj EPS Guidance From $(0.30) to $0.33 Vs $(0.39) Est; Affirms Sales Guidance Of $280.00M Vs $282.16M Est

Benzinga · Nov 8 20:17

Outlook:

For the full year 2024, Fulgent expects:

Core Revenue of approximately $280 million
GAAP loss improvement from approximately ($1.95) per share to approximately ($1.70) per share
Non-GAAP loss improvement from approximately ($0.30) loss per share to approximately $0.33 income per share
Cash, cash equivalents, and investments in marketable securities of approximately $800 million as of December 31, 2024*

*Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the Company's ongoing stock repurchase program or other expenditures outside the ordinary course of business.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Fulgent Genetics Raises FY24 Adj EPS Guidance From $(0.30) to $0.33 Vs $(0.39) Est; Affirms Sales Guidance Of $280.00M Vs $282.16M Est

Risk Disclaimer